Cite
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study.
MLA
Terpos, Evangelos, et al. “Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World ‘POWERFUL’ Study.” Journal of Clinical Medicine, vol. 10, no. 7, Apr. 2021, p. 1509. EBSCOhost, https://doi.org/10.3390/jcm10071509.
APA
Terpos, E., Repousis, P., Lalayanni, C., Hatjiharissi, E., Assimakopoulou, T., Vassilopoulos, G., Pouli, A., Spanoudakis, E., Michalis, E., Pangalis, G., Ntanasis-Stathopoulos, I., Poziopoulos, C., Kyrtsonis, M.-C., Pappa, V., Symeonidis, A., Georgopoulos, C., Zikos, P. M., Gavriatopoulou, M., Papadaki, H. A., & Dadakaridou, M. (2021). Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study. Journal of Clinical Medicine, 10(7), 1509. https://doi.org/10.3390/jcm10071509
Chicago
Terpos, Evangelos, Panagiotis Repousis, Chrysavgi Lalayanni, Evdoxia Hatjiharissi, Theodora Assimakopoulou, Georgios Vassilopoulos, Anastasia Pouli, et al. 2021. “Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World ‘POWERFUL’ Study.” Journal of Clinical Medicine 10 (7): 1509. doi:10.3390/jcm10071509.